Pricing of drugs and donations: options for sustainable equity pricing.

Hdl Handle:
http://hdl.handle.net/10144/17744
Title:
Pricing of drugs and donations: options for sustainable equity pricing.
Authors:
Pérez-Casas, C; Herranz, E; Ford, N
Journal:
Tropical Medicine & International Health
Abstract:
Effective medicines exist to treat or alleviate many diseases which predominate in the developing world and cause high mortality and morbidity rates. Price should not be an obstacle preventing access to these medicines. Increasingly, drug donations have been established by drug companies, but these are often limited in time, place or use. Measures exist which are more sustainable and will have a greater positive impact on people's health. Principally, these are encouraging generic competition; adopting into national legislation and implementing TRIPS safeguards to gain access to cheaper sources of drugs; differential pricing; creating high volume or high demand through global and regional procurement; and supporting the production of quality generic drugs by developing countries through voluntary licenses if needed, and facilitating technology transfer.
Affiliation:
Campaign for Access to Essential Medicines, Médecins sans Frontières, Geneva, Switzerland. carmen_perez@madrid.msf.org
Publisher:
Wiley-Blackwell
Issue Date:
Nov-2001
URI:
http://hdl.handle.net/10144/17744
PubMed ID:
11703854
Additional Links:
http://www.blackwell-synergy.com/loi/tmi
Language:
en
ISSN:
1360-2276
Appears in Collections:
Health Politics

Full metadata record

DC FieldValue Language
dc.contributor.authorPérez-Casas, C-
dc.contributor.authorHerranz, E-
dc.contributor.authorFord, N-
dc.date.accessioned2008-02-07T17:04:06Z-
dc.date.available2008-02-07T17:04:06Z-
dc.date.issued2001-11-
dc.identifier.citationPricing of drugs and donations: options for sustainable equity pricing. 2001, 6 (11):960-4 Trop. Med. Int. Healthen
dc.identifier.issn1360-2276-
dc.identifier.pmid11703854-
dc.identifier.urihttp://hdl.handle.net/10144/17744-
dc.description.abstractEffective medicines exist to treat or alleviate many diseases which predominate in the developing world and cause high mortality and morbidity rates. Price should not be an obstacle preventing access to these medicines. Increasingly, drug donations have been established by drug companies, but these are often limited in time, place or use. Measures exist which are more sustainable and will have a greater positive impact on people's health. Principally, these are encouraging generic competition; adopting into national legislation and implementing TRIPS safeguards to gain access to cheaper sources of drugs; differential pricing; creating high volume or high demand through global and regional procurement; and supporting the production of quality generic drugs by developing countries through voluntary licenses if needed, and facilitating technology transfer.en
dc.language.isoenen
dc.publisherWiley-Blackwell-
dc.relation.urlhttp://www.blackwell-synergy.com/loi/tmi-
dc.rightsArchived on this site with the kind permission of Wiley-Blackwellen
dc.subject.meshAnti-Bacterial Agentsen
dc.subject.meshAnti-HIV Agentsen
dc.subject.meshAntiprotozoal Agentsen
dc.subject.meshDrug Costsen
dc.subject.meshDrug Industryen
dc.subject.meshDrugs, Genericen
dc.subject.meshHIV Infectionsen
dc.subject.meshHealth Services Accessibilityen
dc.subject.meshHumansen
dc.subject.meshLeishmaniasisen
dc.subject.meshMeningitis, Cryptococcalen
dc.subject.meshTrachomaen
dc.subject.meshWorld Healthen
dc.titlePricing of drugs and donations: options for sustainable equity pricing.en
dc.contributor.departmentCampaign for Access to Essential Medicines, Médecins sans Frontières, Geneva, Switzerland. carmen_perez@madrid.msf.orgen
dc.identifier.journalTropical Medicine & International Healthen
All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.